Eli Lilly and Company
@EliLillyandCo
Uniting caring with discovery to create medicines that make life better worldwide. Lilly’s official account (formerly LillyPad)
参加 July 2010
1.2K フォロー中 147.2K ファン
Presented at #EASD2026#, our investigational combination of a selective amylin agonist and GIP/GLP-1 receptor agonist showed promising results in adults with obesity and type 2 diabetes: substantial weight loss and A1C reduction. Read more:
もっと見る
